Immunogenicity is critical in the establishment of an effective adaptive immune response [11, 12] and is largely dependent on tumor-associated antigen presentation by Major Histocompatibility Complex (MHC) class I molecules [13]. The gene discussed is HLA-C; the disease is neoplasm.